Manufacturer of Avatrombopag

In May 2018, the U.S. Food and Drug Administration (FDA) approved Dova Pharmaceuticals for the first time. Avatrombopag, manufactured by Inc., is marketed as a second-generation oral thrombopoietin receptor agonist (TPO-RA) for the treatment of thrombocytopenia in adult patients with chronic liver disease scheduled for surgery and for the treatment of thrombocytopenia in adult patients with chronic immune thrombocytopenia who have had an inadequate response to prior therapy. Avatrombopag is available as a 20 mg oral tablet that should be taken with food. For the treatment of chronic ITP, the initial dose of avatrombopag is 20 mg (1 tablet) once daily.